TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27272518

Group type: EXPERIMENTAL
Intervention: LC-Phototherapy (large cluster probe, 33 diodes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SC-Phototherapy (small cluster probe, 9 diodes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: LC-Placebo (large cluster probe, 33 diodes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: SC-Placebo (small cluster probe, 9 diodes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both LC and SC Phototherapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All conditions tested (LC, SC, LC-placebo, SC-placebo)
Number of subjects: 10
Study: 24388977

Group type: EXPERIMENTAL
Intervention: Fast gamma activity (80-140 Hz) in the septal or posterior region of the hippocampus (bilaterally)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fast gamma activity (80-140 Hz)
Number of subjects: 24
Study: 23241439

Group type: EXPERIMENTAL
Intervention: Sunitinib Conventional Continuation Strategy (CCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug Free Interval Strategy (DFIS)
Number of subjects: 0
Study: 20360291

Group type: EXPERIMENTAL
Intervention: Computed tomographic coronary artery calcium assessment (CT CAC)
Number of subjects: 263
Study: 17377504

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.05 mg/kg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 15789598

Group type: EXPERIMENTAL
Intervention: Pearson's correlation
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Cosine coefficient
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Goodman and Kruskal's Gamma coefficient
Number of subjects: 318

Group type: COMPARATOR
Intervention: Other nine similarity measures
Number of subjects: 318
Study: 11886906

Group type: EXPERIMENTAL
Intervention: Intramedullary nail (Proximal Femoral Nail)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 95 fixed‐angle screw‐plate (Dynamic Condylar Screw)
Number of subjects: 39
Study: 9841603

Group type: EXPERIMENTAL
Intervention: Proton‐pump inhibitor (omeprazole or lansoprazole), amoxicillin, and either clarithromycin or ecabet sodium
Number of subjects: 35

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 35
Study: 7621685

Group type: EXPERIMENTAL
Intervention: Mesigyna
Number of subjects: 5680

Group type: EXPERIMENTAL
Intervention: Cyclofem
Number of subjects: 5680

Group type: EXPERIMENTAL
Intervention: Injectable No. 1
Number of subjects: 5680
Study: 2642284

Group type: EXPERIMENTAL
Intervention: Multidimensional evaluation by an interdisciplinary geriatric consultation team
Number of subjects: 178

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 178
Study: 351716

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel administered extraamniotically
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combined treatment (i.v. oxytocin, 20% NaCl solution, Premarin, balloon catheter, Rivanol)
Number of subjects: 20
Study: 30264293

Group type: EXPERIMENTAL
Intervention: E6201, an intravenous MEK1 inhibitor
Number of subjects: 1
Study: 28603112

Group type: EXPERIMENTAL
Intervention: Safoof akseer e jigar (test drug)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Interferon Alpha (control therapy)
Number of subjects: 87
Study: 25524478

Group type: EXPERIMENTAL
Intervention: Cetuximab with PX-866 (8 mg p.o. daily)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cetuximab without PX-866
Number of subjects: 83
Study: 24188184

Group type: EXPERIMENTAL
Intervention: Internal jugular veins (IJVs) in MS patients with CCSVI during head rotation
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Internal jugular veins (IJVs) in MS patients with CCSVI
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: CCSVI scores in MS patients
Number of subjects: 313
Study: 21220064

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for PTSD treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 66
Study: 19736332

Group type: EXPERIMENTAL
Intervention: Antipyretic agents (rectal diclofenac followed by oral ibuprofen or acetaminophen)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 17577104

Group type: EXPERIMENTAL
Intervention: Azelnidipine 8 to 16 mg (average 14.5 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Amlodipine 2.5 to 7.5 mg (average 4.9 mg)
Number of subjects: 47
Study: 15025886

Group type: EXPERIMENTAL
Intervention: Homeopathic vital force ratings
Number of subjects: 62
Study: 10783649

Group type: EXPERIMENTAL
Intervention: Formoterol (24 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9115054

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment initiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment discontinuation
Number of subjects: 0
Study: 8416468

Group type: EXPERIMENTAL
Intervention: Essential fatty acids
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 3086023

Group type: EXPERIMENTAL
Intervention: Intravenous nutrition with hypertonic glucose at energy intakes of 6650 to 17,100 kJ/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous nutrition with hypertonic glucose
Number of subjects: 0
Study: 30549292

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 29165106

Group type: EXPERIMENTAL
Intervention: Progressive VDU lenses (VDU group)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Progressive lenses (P group)
Number of subjects: 35
Study: 26052959

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV) during CPB
Number of subjects: 50

Group type: COMPARATOR
Intervention: No mechanical ventilation (MV) during CPB
Number of subjects: 50
Study: 23952947

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 52

Group type: COMPARATOR
Intervention: Other antihypertensive drugs
Number of subjects: 52
Study: 21371369

Group type: EXPERIMENTAL
Intervention: Evoked response audiometry
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pure tone audiometry
Number of subjects: 25

Group type: COMPARATOR
Intervention: Scrub typhus
Number of subjects: 25
Study: 19695405

Group type: EXPERIMENTAL
Intervention: Generic enoxaparin 60 mg SC
Number of subjects: 22

Group type: COMPARATOR
Intervention: Branded enoxaparin 60 mg SC
Number of subjects: 22
Study: 16897979

Group type: EXPERIMENTAL
Intervention: S‐1 + biweekly docetaxel (DOC) combination therapy
Number of subjects: 33
Study: 12768557

Group type: EXPERIMENTAL
Intervention: Normalized uterine artery pulsatility index (PI)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Non-normalized uterine artery PI
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Normalized uterine artery PI
Number of subjects: 126
Study: 10757544

Group type: EXPERIMENTAL
Intervention: High-fat diet (39.5% calories as fat) without red wine for 30 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-fat diet (39.5% calories as fat) with red wine (240 mL/d) for 30 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control diet (27% calories as fat) without red wine for 30 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control diet (27% calories as fat) with red wine (240 mL/d) for 30 days
Number of subjects: 11
Study: 9015522

Group type: EXPERIMENTAL
Intervention: Monovalent anti-B. atrox antivenom (group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Polyvalent (Crotalinae) antivenom (group B)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both antivenoms
Number of subjects: 39
Study: 1633702

Group type: EXPERIMENTAL
Intervention: Topical cyclosporin (CS) formulation (10%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flumethasone pivalate (FP) formulation (0.02%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 6649755

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 22

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 22
Study: 30771825

Group type: EXPERIMENTAL
Intervention: Subscapularis tenotomy (ST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lesser tuberosity osteotomy (LTO)
Number of subjects: 60
Study: 27194263

Group type: EXPERIMENTAL
Intervention: Constant Force Feedback (CFF)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bandwidth Force Feedback (BFF)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Fade-in Force Feedback
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All groups (CFF, BFF, Fade-in)
Number of subjects: 51
Study: 26840505

Group type: EXPERIMENTAL
Intervention: Xanthohumol drink (12 mg XN/P/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pure Xanthohumol in a follow-up study (n = 10)
Number of subjects: 22
Study: 24751788

Group type: EXPERIMENTAL
Intervention: Clonidine 1 μg/kg/hr
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 22952182

Group type: EXPERIMENTAL
Intervention: Vitamin A (600 μg retinyl palmitate/d)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vitamin A (300 μg retinyl palmitate/d)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vitamin A + zinc (10 or 20 mg zinc sulfate/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 20212335

Group type: EXPERIMENTAL
Intervention: Artesunate (AS) + Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Artesunate (AS) + Amodiaquine (AQ)
Number of subjects: 160
Study: 17285405

Group type: EXPERIMENTAL
Intervention: Intravenous-based (IV) anesthesia with modified neurolept anesthesia (droperidol 0.2 mg/kg and pentazocine 0.15-0.3 mg/kg) and postoperative intravenous infusion of buprenorphine (20 µg/ml) via PCA pump.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural-based (EPI) anesthesia with combined epidural analgesia and general anesthesia (sevoflurane and nitrous oxide) followed by epidural infusion of 0.125% bupivacaine and 5 µg/ml buprenorphine.
Number of subjects: 30
Study: 15644018

Group type: EXPERIMENTAL
Intervention: Classic Laryngeal Mask Airway (CLMA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Portex Soft Seal Laryngeal Mask Airway (PLMA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 42
Study: 11851643

Group type: EXPERIMENTAL
Intervention: L-N(G)-monomethyl arginine (LNMMA) at doses of 0.1, 0.3, 1.0 and 3.0 mg kg‐1 min‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study: 10201745

Group type: EXPERIMENTAL
Intervention: Modified Epley maneuver
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Modified Epley maneuver with augmented head rotations
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Modified Semont maneuver
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 87
Study: 7775331

Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1320279

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral stress management (CBSM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Assessment-only controls (HIV-1 seropositive and seronegative)
Number of subjects: 65
Study: 6474386

Group type: EXPERIMENTAL
Intervention: Positively ionised air (5‐10 X 10(5) ions/cm)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control air (not ionised)
Number of subjects: 12
Study: 30921490

Group type: EXPERIMENTAL
Intervention: 200 mg of plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD) in oral solution (Epidiolex, 100 mg/mL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 200 mg of CBD
Number of subjects: 38
Study: 30136062

Group type: EXPERIMENTAL
Intervention: Training Program to Improve Home Visitor Communication
Number of subjects: 0
Study: 25667244

Group type: EXPERIMENTAL
Intervention: Nasal synchronized intermittent positive pressure ventilation (NSIPPV)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Bilevel continuous positive airway pressure (BiPAP)
Number of subjects: 124
Study: 23810328

Group type: EXPERIMENTAL
Intervention: Penthrox
Number of subjects: 251
Study: 21784820

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 59

Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 59
Study: 19778983

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 4130

Group type: EXPERIMENTAL
Intervention: Folic acid-iron
Number of subjects: 4130

Group type: EXPERIMENTAL
Intervention: Folic acid-iron-zinc
Number of subjects: 4130

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients
Number of subjects: 4130

Group type: COMPARATOR
Intervention: Controls (vitamin A only)
Number of subjects: 4130

Group type: EXPERIMENTAL
Intervention: Maternal iron-folic acid supplementation
Number of subjects: 4130
Study: 16933434

Group type: EXPERIMENTAL
Intervention: Conjoint group treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender-specific group treatment
Number of subjects: 0
Study: 15120711

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (120 microg/day p.o.)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no beraprost sodium)
Number of subjects: 44
Study: 11402826

Group type: EXPERIMENTAL
Intervention: Topical dorzolamide eye drops, 3 times daily for a mean follow up of 9 months
Number of subjects: 28
Study: 9364107

Group type: EXPERIMENTAL
Intervention: In vivo techniques training (N=29)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Classroom techniques training (N=13)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No-treatment control group (N=15)
Number of subjects: 57
Study: 1414289

Group type: EXPERIMENTAL
Intervention: Primary argon laser trabeculoplasty
Number of subjects: 82

Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 82
Study: 4035650

Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT III) substitution
Number of subjects: 51

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of AT III and Heparin
Number of subjects: 51
Study: 30758329

Group type: EXPERIMENTAL
Intervention: 600 mg CBD
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 29420749

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation group (Prosure®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non‐intervention group
Number of subjects: 0
Study: 26647415

Group type: EXPERIMENTAL
Intervention: Diabetes group visits with individualized sessions and diabetes self-management education
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 80
Study: 24643901

Group type: EXPERIMENTAL
Intervention: Heliox-driven bronchodilation therapy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Air-driven bronchodilation therapy
Number of subjects: 132
Study: 23257487

Group type: EXPERIMENTAL
Intervention: Thermo-mechanical cycling (TMC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water storage at 37C for 24 hours (Control)
Number of subjects: 100
Study: 19815809

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 288
Study: 18808627

Group type: EXPERIMENTAL
Intervention: Tactile touch intervention (n = 21)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard treatment (control group, n = 23)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison between intervention and control groups
Number of subjects: 44
Study: 16160598

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg orally twice daily on the day before and the day of contrast administration)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no acetylcysteine, saline 0.9% intravenously at 1 mL/kg/h for 12 hours before and after contrast administration)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine >2.5 mg/dL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline serum creatinine <2.5 mg/dL
Number of subjects: 50
Study: 12034044

Group type: EXPERIMENTAL
Intervention: Interferon‐alpha2b (IFN‐alpha2b) 5 MU three times a week for 24 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 76
Study: 9919322

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) combined with interpersonal psychotherapy (IPT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with Nortriptyline (NT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo combined with interpersonal psychotherapy (IPT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Maintenance monthly IPT (combined with NT or placebo)
Number of subjects: 180
Study: 8787856

Group type: EXPERIMENTAL
Intervention: Temporary high-dose rate 125I implant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Permanent low-dose rate 125I implant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quality assurance methodology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Future adjuvant application of hyperthermia
Number of subjects: 0
Study: 1704550

Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DDD pacing with AV interval 75 msec
Number of subjects: 10

Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 10
Study: 113716

Group type: EXPERIMENTAL
Intervention: Cuprenil and Chelaton Polfa (radiosensitizers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no radiosensitizers)
Number of subjects: 0
Study: 31077299

Group type: EXPERIMENTAL
Intervention: High baseline alpha‐tocopherol (fifth quintile [Q5])
Number of subjects: 22881

Group type: EXPERIMENTAL
Intervention: Serum alpha‐tocopherol at 3 years (Q5)
Number of subjects: 22881

Group type: EXPERIMENTAL
Intervention: Lower serum alpha‐tocopherol at baseline with greater increases at 3 years (third tertile)
Number of subjects: 22881
Study: 30857609

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 4 mg with ropivacaine 0.75% (3 ml) and saline (1 ml)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 4 mg with perineural saline (1 ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group with perineural saline (1 ml) and intravenous saline (1 ml)
Number of subjects: 24
Study: 27207016

Group type: EXPERIMENTAL
Intervention: Noninvasive model constructed using aspartate aminotransferase, HBsAg, platelet, and albumin as predictors
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Noninvasive model with a cut-off point of -0.96
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Noninvasive model with a cut-off point of 0.96
Number of subjects: 298
Study: 26507458

Group type: EXPERIMENTAL
Intervention: Nefopam + modulated electro-hyperthermia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nefopam without hyperthermia
Number of subjects: 12
Study: 23450051

Group type: EXPERIMENTAL
Intervention: Hydrocortisone therapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 21073895

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network for predicting significant fibrosis (ANN-SF)
Number of subjects: 362
Study: 19475410

Group type: EXPERIMENTAL
Intervention: NaP + laxative
Number of subjects: 35

Group type: COMPARATOR
Intervention: NaP
Number of subjects: 35

Group type: COMPARATOR
Intervention: PEG
Number of subjects: 35
Study: 17373902

Group type: EXPERIMENTAL
Intervention: Targeted or biological therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer chemotherapeutic agents
Number of subjects: 0
Study: 14729785

Group type: EXPERIMENTAL
Intervention: Uric acid (UA) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11552018

Group type: EXPERIMENTAL
Intervention: OXC 2400 mg/day
Number of subjects: 143

Group type: COMPARATOR
Intervention: OXC 300 mg/day
Number of subjects: 143
Study: 9747173

Group type: EXPERIMENTAL
Intervention: PdB (new surgical instrument)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No PdB (control group)
Number of subjects: 100
Study: 10138808

Group type: EXPERIMENTAL
Intervention: Direct mail intervention (Call Fast, Call 911 campaign) - six direct mail pieces over a 1-year period
Number of subjects: 130000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 130000
Study: 3050248

Group type: EXPERIMENTAL
Intervention: Fine needle aspiration biopsy technique
Number of subjects: 21
Study: 30429127

Group type: COMPARATOR
Intervention: High carbohydrate diet (60%, n=54)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet (40%, n=53)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (20%, n=57)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (20%)
Number of subjects: 164
Study: 27913910

Group type: COMPARATOR
Intervention: Control arm (no price display)
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Single Median Price arm
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: Paired Internal/External Median Prices arm
Number of subjects: 1205
Study: 26711384

Group type: EXPERIMENTAL
Intervention: Limited margins IMRT with temozolomide chemotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine margins IMRT with temozolomide chemotherapy
Number of subjects: 50
Study: 23275036

Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZ) 1,000 mg intravenous administration (single dose)
Number of subjects: 32
Study: 20644497

Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus CTV‐05 (LACTIN‐V) administered by a vaginal applicator at 2 × 10 colony‐forming units (cfu)/dose for 5 days followed by weekly application for 2 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17851681

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg/kg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 22
Study: 15735098

Group type: EXPERIMENTAL
Intervention: Low-isoflavone soy protein isolate (SPI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High-isoflavone soy protein isolate (SPI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 35